Ascelia Pharma

Ascelia Pharma is a Malmö-based pharmaceutical company that developed Orviglance (manganese chloride tetrahydrate), an EU-approved MRI contrast agent for liver imaging. Orviglance is the first new liver-specific MRI contrast agent in over 15 years and provides an alternative for patients who cannot receive gadolinium-based contrast. Listed on Nasdaq Stockholm, Ascelia Pharma is commercializing Orviglance across European markets.